Stereochemistry | ACHIRAL |
Molecular Formula | C14H18N2O3.ClH |
Molecular Weight | 298.765 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCN(CC)CCN1C(=O)OC2=C(C=CC=C2)C1=O
InChI
InChIKey=QPFDPUCWRFYCFB-UHFFFAOYSA-N
InChI=1S/C14H18N2O3.ClH/c1-3-15(4-2)9-10-16-13(17)11-7-5-6-8-12(11)19-14(16)18;/h5-8H,3-4,9-10H2,1-2H3;1H
Molecular Formula | C14H18N2O3 |
Molecular Weight | 262.3043 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Letimide is a new analgesic. It is a cyclic derivative of a salicylamide. The analgesic effect of this drug as determined in rats showed a higher potency than aspirin, but was without anti-inflammatory and antipyretic activity. Letimide is not a genotoxic agent according to the cytogenetic damage observed in vivo and in vitro, and would seem to justify other preclinical and clinical studies to confirm its lack of toxicity. Known adverse effects are headache and dizziness.